DE69836139D1 - Verfahren zur behandlung von vaskulären proliferativen erkrankungen mit p27 und fusionen davon - Google Patents
Verfahren zur behandlung von vaskulären proliferativen erkrankungen mit p27 und fusionen davonInfo
- Publication number
- DE69836139D1 DE69836139D1 DE69836139T DE69836139T DE69836139D1 DE 69836139 D1 DE69836139 D1 DE 69836139D1 DE 69836139 T DE69836139 T DE 69836139T DE 69836139 T DE69836139 T DE 69836139T DE 69836139 D1 DE69836139 D1 DE 69836139D1
- Authority
- DE
- Germany
- Prior art keywords
- fusions
- treatment
- proliferative diseases
- vascular proliferative
- vascular
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
- C12N9/1211—Thymidine kinase (2.7.1.21)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4703—Inhibitors; Suppressors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/897,333 US6177272B1 (en) | 1997-07-21 | 1997-07-21 | Method for treating vascular proliferative diseases with p27 and fusions thereof |
US897333 | 1997-07-21 | ||
PCT/US1998/015025 WO1999003508A2 (en) | 1997-07-21 | 1998-07-21 | METHOD FOR TREATING VASCULAR PROLIFERATIVE DISEASES WITH p27 AND FUSIONS THEREOF |
Publications (2)
Publication Number | Publication Date |
---|---|
DE69836139D1 true DE69836139D1 (de) | 2006-11-23 |
DE69836139T2 DE69836139T2 (de) | 2007-08-16 |
Family
ID=25407780
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69836139T Expired - Fee Related DE69836139T2 (de) | 1997-07-21 | 1998-07-21 | Verfahren zur behandlung von vaskulären proliferativen erkrankungen mit p27 und fusionen davon |
Country Status (8)
Country | Link |
---|---|
US (2) | US6177272B1 (de) |
EP (1) | EP0998307B1 (de) |
JP (1) | JP2001510028A (de) |
AT (1) | ATE342067T1 (de) |
AU (1) | AU8502198A (de) |
CA (1) | CA2295199C (de) |
DE (1) | DE69836139T2 (de) |
WO (1) | WO1999003508A2 (de) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6420345B1 (en) * | 1999-03-01 | 2002-07-16 | Cell Genesys, Inc. | Methods and reagents for inhibiting angiogenesis |
JP2003523722A (ja) | 1999-03-01 | 2003-08-12 | セル ジェネシス インコーポレイテッド | 抗新生物性組成物およびその使用 |
US6413943B1 (en) * | 1999-03-01 | 2002-07-02 | Cell Genesys, Inc. | Methods and reagents for inhibiting proliferation of smooth muscle cells |
AU7320200A (en) | 1999-09-22 | 2001-04-24 | Hitoshi Kohsaka | P21cip1 remedies for rheumatism |
US8236048B2 (en) * | 2000-05-12 | 2012-08-07 | Cordis Corporation | Drug/drug delivery systems for the prevention and treatment of vascular disease |
US6776796B2 (en) | 2000-05-12 | 2004-08-17 | Cordis Corportation | Antiinflammatory drug and delivery device |
US20040243097A1 (en) * | 2000-05-12 | 2004-12-02 | Robert Falotico | Antiproliferative drug and delivery device |
US20050002986A1 (en) * | 2000-05-12 | 2005-01-06 | Robert Falotico | Drug/drug delivery systems for the prevention and treatment of vascular disease |
US7261735B2 (en) * | 2001-05-07 | 2007-08-28 | Cordis Corporation | Local drug delivery devices and methods for maintaining the drug coatings thereon |
DE60124285T3 (de) * | 2000-09-29 | 2011-03-17 | Cordis Corp., Miami Lakes | Beschichtete medizinische geräte |
US20020111590A1 (en) * | 2000-09-29 | 2002-08-15 | Davila Luis A. | Medical devices, drug coatings and methods for maintaining the drug coatings thereon |
US20020051730A1 (en) * | 2000-09-29 | 2002-05-02 | Stanko Bodnar | Coated medical devices and sterilization thereof |
US20030013638A1 (en) * | 2001-01-22 | 2003-01-16 | Marks Andrew R. | P27 prevents cellular migration |
US20020098998A1 (en) * | 2001-01-22 | 2002-07-25 | Marks Andrew R. | P27 prevents cellular migration |
US7195640B2 (en) * | 2001-09-25 | 2007-03-27 | Cordis Corporation | Coated medical devices for the treatment of vulnerable plaque |
US7108701B2 (en) * | 2001-09-28 | 2006-09-19 | Ethicon, Inc. | Drug releasing anastomosis devices and methods for treating anastomotic sites |
US20030065377A1 (en) * | 2001-09-28 | 2003-04-03 | Davila Luis A. | Coated medical devices |
US20030065345A1 (en) * | 2001-09-28 | 2003-04-03 | Kevin Weadock | Anastomosis devices and methods for treating anastomotic sites |
WO2006031210A1 (en) * | 2003-05-29 | 2006-03-23 | Board Of Regents, The University Of Texas Systems | Jabi as a prognostic marker and a therapeutic target for human cancer |
US7833339B2 (en) | 2006-04-18 | 2010-11-16 | Franklin Industrial Minerals | Mineral filler composition |
CA2715765A1 (en) | 2008-02-19 | 2009-08-27 | Celladon Corporation | Compositions for enhanced uptake of viral vectors in the myocardium |
CA3146023A1 (en) | 2019-07-05 | 2021-01-14 | Iomx Therapeutics Ag | Antibodies binding igc2 of igsf11 (vsig3) and uses thereof |
WO2022008027A1 (en) | 2020-07-06 | 2022-01-13 | Iomx Therapeutics Ag | Antibodies binding igv of igsf11 (vsig3) and uses thereof |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5328470A (en) * | 1989-03-31 | 1994-07-12 | The Regents Of The University Of Michigan | Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor |
US6242575B1 (en) | 1994-01-07 | 2001-06-05 | Fred Hutchinson Institute For Cancer Research | Antibodies for detecting p27 protein |
US6355774B1 (en) | 1994-01-07 | 2002-03-12 | Fred Hutchinson Cancer Research Center | Isolated p27 protein |
US6316208B1 (en) | 1994-01-07 | 2001-11-13 | Memorial Sloan-Kettering Cancer Center | Methods for determining isolated p27 protein levels and uses thereof |
US5688665A (en) * | 1994-01-07 | 1997-11-18 | Fred Hutchinson Cancer Research Center | Isolated nucleic acid molecules encoding the p27 KIP-1 protein |
US6635450B1 (en) | 1994-07-15 | 2003-10-21 | Fred Hutchinson Institute For Cancer Research | Isolated P27 protein, nucleic acid molecules encoding same, methods of identifying agents acting on same, and uses of said agents |
AU5297496A (en) * | 1995-02-17 | 1996-09-04 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Methods of preparation and use of recombinant adenoviral vectors |
US5962424A (en) * | 1995-02-21 | 1999-10-05 | Arch Development Corporation | Methods and compositions for targeting selectins |
US5863904A (en) * | 1995-09-26 | 1999-01-26 | The University Of Michigan | Methods for treating cancers and restenosis with P21 |
US6541197B2 (en) * | 1996-01-22 | 2003-04-01 | Human Gene Therapy Research Institute | Vehicles for stable transfer of green fluorescent protein gene and methods of use for same |
US5672508A (en) * | 1996-01-23 | 1997-09-30 | Mitotix, Inc. | Inhibitors of cell-cycle progression, and uses related thereto |
WO1998021350A1 (en) * | 1996-11-13 | 1998-05-22 | Board Of Regents, The University Of Texas System | Diminishing viral gene expression by promoter replacement |
-
1997
- 1997-07-21 US US08/897,333 patent/US6177272B1/en not_active Expired - Fee Related
-
1998
- 1998-07-21 AU AU85021/98A patent/AU8502198A/en not_active Abandoned
- 1998-07-21 EP EP98935852A patent/EP0998307B1/de not_active Expired - Lifetime
- 1998-07-21 JP JP2000502802A patent/JP2001510028A/ja active Pending
- 1998-07-21 CA CA002295199A patent/CA2295199C/en not_active Expired - Fee Related
- 1998-07-21 DE DE69836139T patent/DE69836139T2/de not_active Expired - Fee Related
- 1998-07-21 AT AT98935852T patent/ATE342067T1/de not_active IP Right Cessation
- 1998-07-21 WO PCT/US1998/015025 patent/WO1999003508A2/en active IP Right Grant
-
2000
- 2000-11-07 US US09/708,276 patent/US6884431B1/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
WO1999003508A2 (en) | 1999-01-28 |
EP0998307A2 (de) | 2000-05-10 |
JP2001510028A (ja) | 2001-07-31 |
AU8502198A (en) | 1999-02-10 |
EP0998307B1 (de) | 2006-10-11 |
CA2295199C (en) | 2007-07-03 |
US6177272B1 (en) | 2001-01-23 |
CA2295199A1 (en) | 1999-01-28 |
DE69836139T2 (de) | 2007-08-16 |
WO1999003508A3 (en) | 1999-04-08 |
WO1999003508A9 (en) | 1999-05-14 |
ATE342067T1 (de) | 2006-11-15 |
US6884431B1 (en) | 2005-04-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69836139D1 (de) | Verfahren zur behandlung von vaskulären proliferativen erkrankungen mit p27 und fusionen davon | |
ATE338813T1 (de) | Methode zur tumorbehandlung mit alloaktivierten humanen lymphozyen | |
ATE262336T1 (de) | Verwendung von 9-desoxy-2',9-alpha-methano-3-oxa- 4,5,6-trinor-3,7-(1',3'-interphenylen)-13,14- dihydroprostaglandin-f1 zur behandlung von peripheren vaskulären erkrankungen | |
NZ504026A (en) | Methods for treating hypercoagulable states or acquired protein C deficiency using human-activated protein C | |
DE59711321D1 (de) | Neue substituierte pyrazolderivate zur behandlung von herzkreislauferkrankungen | |
ATE221377T1 (de) | Verfahren zur reduzierung der körperfettanteils bei tieren mit der verabreichungvon konjugiergter linolsäure | |
ES2133413T3 (es) | Gel de lecitina inyectable. | |
DE69609868D1 (de) | Neue steroidester zur behandlung von hauterkrankungen | |
DE60030769D1 (de) | Verfahren zur behandlung von entzündungen | |
DE69942365D1 (de) | Gezielte zufuhr von pharmazeutischen agenzien zu verletzten geweben | |
DE69634900D1 (de) | Proteintyrosine-kinaseinhibitoren zur behandlung der osteoarthritis | |
DE69535264D1 (de) | Verfahren zur behandlung von diabetes mittels kgf | |
DE69929787D1 (de) | Verfahren zur behandlung von neurologischen erkrankungen mit hilfe der bestimmung des bche genotyps | |
DE60035693D1 (de) | Zusammensetzung und verfahren zur behandlung von immunverwandten krankheiten | |
DE69631656D1 (de) | Debromhymenialdisin und verwandte verbindungen zur behandlung von osteoarthritis | |
DE69512760D1 (de) | Verwendung von Melatonin zur Behandlung von Patienten die an Drogenabhängigkeit leiden | |
ATE217191T1 (de) | Verwendung von phanquinon zur behandlung von alzheimer's krankheit | |
DE60015791D1 (de) | Verfahren zur herstellung von mikania extrakten enthaltend mikanolide und dihydromikanolide und verwendung in der behandlung proliferativer erkrankungen | |
DE69739737D1 (de) | Methode zur Behandlung von Muskelkrankheiten | |
DE59508509D1 (de) | Dna-expressionsvektoren zur verwendung in der gentherapeutischen behandlung von gefässerkrankungen | |
ATE270102T1 (de) | Verwendung von benzopyranolen zur behandlung von neurologischen erkrankungen | |
DE69533311D1 (de) | Verfahren zur behandlung von autoimmunerkrankungen mittels typ-1-interferonen | |
ATA901396A (de) | Verwendung von melatonin zur behandlung von an medikamentensucht leidenden patienten | |
ID23184A (id) | Garam-garam peptida bpc dengan aktivitas organoprotektif proses pembuatan dan penggunaannya dalam terapi | |
DE69818809D1 (de) | Verfahren zur behandlung von narbengewebe |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition | ||
8339 | Ceased/non-payment of the annual fee |